Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer.

Trial Profile

Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel; Trastuzumab
  • Indications Breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ELATE
  • Most Recent Events

    • 05 Nov 2010 Planned initiation date changed from 1 Oct 2010 to 1 Nov 2010, according to ClinicalTrials.gov.
    • 28 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top